# GPT-5.2 Review

**Role:** External referee review
**Model:** openai/gpt-5.2
**Paper:** paper.pdf
**Timestamp:** 2026-02-20T08:57:25.904282
**Route:** OpenRouter + LaTeX
**Review mode:** Tri-model (3 independent reviewers)
**Tokens:** 22144 in / 4689 out
**Response SHA256:** 9f63170c0b1d5347

---

## Referee Report: “Where Medicaid Goes Dark: A Claims-Based Atlas of Provider Deserts and the Resilience of Supply to Enrollment Shocks”

### Summary
The paper uses newly released T‑MSIS provider spending/encounter data (2018Q1–2024Q3; 227M provider–service records) linked to NPPES to (i) construct a county-by-specialty, claims-based “atlas” of Medicaid provider deserts and (ii) estimate the causal effect of post‑pandemic Medicaid enrollment “unwinding” on provider supply using staggered state variation in timing and intensity of disenrollment. The headline finding is a precisely estimated near-zero effect of unwinding intensity on active Medicaid clinician counts, supported by event studies and permutation inference. The descriptive atlas is striking (e.g., extremely high “desert” prevalence for psychiatry and OB‑GYN) and the measurement contribution—mapping NP/PA taxonomy into specialty groups—could be valuable.

Overall, the project is promising and potentially publishable in a top field or general-interest outlet, but there are several **high-stakes measurement and interpretation issues** that must be addressed to make the causal null credible and the descriptive “desert” concept policy-relevant (especially given the extreme desert rates). The biggest risks are (1) whether the outcome is a noisy proxy for true supply (billing NPI vs servicing NPI; address vs practice site; suppression), (2) whether the “desert threshold” is meaningful for specialty care, and (3) whether the DiD design is adequately tailored to continuous “intensity” treatment with limited adoption-time variation.

---

# 1. FORMAT CHECK (fixable but should be flagged)

### Length
- Appears to be **well over 25 pages** in 12pt, 1.5 spacing, with many figures/tables plus appendix. Roughly “journal length” (likely 35–50 pages in current formatting). **Pass**.

### References
- The in-text citations cover some classic Medicaid access papers and modern DiD papers (Sun & Abraham; Callaway & Sant’Anna; Goodman-Bacon; de Chaisemartin & D’Haultfoeuille; Cameron et al.).
- However, the bibliography is not shown in the LaTeX excerpt (only `\bibliography{references}`), so I cannot verify completeness. Based on in-text citations, it’s a decent start but **missing several key related literatures** (see Section 4).

### Prose (bullets vs paragraphs)
- Major sections are written in paragraphs. Bullets are used appropriately in data appendix and variable lists. **Pass**.

### Section depth
- Introduction, Background, Data, Descriptive results, Empirical strategy, Results, Robustness, Discussion all have multiple substantive paragraphs. **Pass**.

### Figures
- In LaTeX source, figures are referenced via `\includegraphics{...}` with captions and notes. I cannot visually inspect axes/data here. **Do not flag as broken** (per your instruction), but when submitting you should ensure:
  - all maps have legends/colorbars, units, and a clear definition of “0” vs missing,
  - time-series figures have y-axis labels and units (counts vs per-capita).

### Tables
- Tables contain real numbers with SEs, CIs, N. **Pass**.

---

# 2. STATISTICAL METHODOLOGY (CRITICAL)

### a) Standard errors
- Main regression tables report SEs in parentheses (e.g., Table 6 / `tab:main_by_spec`). **Pass**.

### b) Significance testing
- Inference is conducted via clustered SEs, plus permutation inference and placebo. **Pass**.

### c) Confidence intervals
- Table 6 includes 95% CIs; event study notes 95% CI. **Pass**.

### d) Sample sizes
- N reported for all regressions in main tables. **Pass**.

### e) DiD with staggered adoption
- You explicitly cite and claim to implement Sun & Abraham interaction-weighted estimator as robustness. That is good.
- However, there is an internal tension: the *main* design is **not a classic binary staggered DiD** but a **continuous intensity × post** design where the *timing* is clustered (most states start in 2023Q2). In that setting:
  - TWFE contamination from already-treated controls is less of the usual problem, but **identification hinges on “parallel trends in outcomes with respect to intensity”** (i.e., states that will unwind more intensely would have had similar post-2023Q2 trends absent unwinding).
  - The Sun-Abraham estimator is designed for discrete treatment cohorts; it is less clear it is the right robustness tool for a continuous intensity treatment. You need to be precise about what Sun-Abraham is estimating in your implementation (what is the “treatment” variable for IW?).
- Recommendation: Add a short subsection clarifying:
  1) what estimand you want (effect per 1pp disenrollment?),
  2) what variation identifies it (cross-state intensity differences after start),
  3) whether you can interpret it as an “event study with continuous dose,” and
  4) why the chosen estimator is appropriate.

### f) RDD
- Not applicable.

### Additional inference concerns (important)
1. **Clustering with 51 clusters is probably OK**, but given a very large panel and highly aggregated treatment variation, I’d like to see **wild cluster bootstrap** p-values as a robustness check (e.g., Roodman et al. methods). Permutation inference helps, but it permutes timing/intensity and may not mimic the true error correlation structure if there are region shocks.

2. **Outcome functional form**: log(active+1) is sensible given zeros, but with desert prevalence near 90–99% in many specialties, the distribution is extremely zero-inflated. The log(·+1) model may be dominated by extensive-margin changes that are mechanically hard to detect if most counties are always at zero. Consider:
   - a count model (Poisson PML with high-dimensional FE; robust SE clustered by state),
   - or a two-part model: Pr(active>0) and E[log(active)|active>0].
   This matters because “no effect” could mean “no movement in already-zero counties” while there could be meaningful changes in counties with some baseline supply.

**Bottom line on methodology**: You meet the “minimum bar” for inference, but the design and outcome distribution raise concerns that should be addressed to make the null result persuasive rather than a byproduct of limited variation/informative sample.

---

# 3. IDENTIFICATION STRATEGY

### Credibility
Strengths:
- Clear exposition of the DiD equation with county×specialty FE and quarter FE.
- Event study shown with 8 pre-period coefficients and joint pre-trend test.
- Placebo (fake treatment date) and permutation inference.

Key concerns / needed clarifications:

1. **What is exogenous: timing vs intensity?**  
   Timing variation is modest (40 states in 2023Q2; 10 in 2023Q3; OR in 2023Q4). So most identifying power must come from **intensity differences**. But intensity (net disenrollment rate) is plausibly correlated with:
   - administrative capacity and reporting quality (also affecting T‑MSIS encounter completeness),
   - Medicaid renewal “procedural disenrollment” aggressiveness (could correlate with provider billing/encounter submission),
   - managed care penetration and encounter data quality,
   - contemporaneous state budget/Medicaid rate changes.
   
   The paper gestures at some of this, but for a top journal you should do more:
   - Show **balance/correlates of intensity**: regress intensity on pre-period provider trends, MCO penetration, baseline Medicaid fees, scope-of-practice laws, unemployment shocks, etc.
   - At minimum, present a table: “State characteristics by intensity quartile.”

2. **Parallel trends should be about *dose***  
   Your event study interacts event time with *state intensity* (good). But I want to see:
   - event studies **by specialty and by baseline desert status / baseline provider quartile** (not just in appendix text saying “p>0.10”),
   - a figure/table showing that pre-trends are flat **in the subset of counties that are “at risk”** (non-zero baseline or near-threshold counties). If 80–90% are zeros, pooled pre-trends can look flat even if the relevant margin is elsewhere.

3. **Treatment definition: cumulative net disenrollment rate**  
   You use a time-invariant intensity `d_g` switched on after start. But disenrollment occurs gradually over months/quarters and differs in pace. A more credible “dose over time” approach would use **quarter-specific disenrollment** (e.g., cumulative disenrollment by quarter, or monthly/quarterly change in enrollment) rather than a constant post indicator times eventual net decline. Otherwise you risk mis-timing: in 2023Q2 a state might have started unwinding but had not yet disenrolled many people, yet is assigned the full “dose” immediately after start. This will mechanically attenuate dynamic effects and flatten event studies.

   Suggestion: Construct `Intensity_{g,t}` as cumulative disenrollment *up to quarter t* (relative to peak), not a constant. Then estimate a distributed lag or event-study with that varying dose.

4. **Interpretation of null**  
   The discussion offers several mechanisms (diluted payer mix, lumpy exit, composition). Those are plausible, but the paper currently does not separate “providers didn’t exit” from “claims/encounters didn’t change because of reporting, suppression, or billing entity aggregation.” The biggest threat is measurement.

### Robustness and placebo
- Placebo date is good, but it is still within the COVID/continuous enrollment period. Consider an additional placebo:
  - use a pre-period “pseudo unwinding” where you randomly assign start quarters in 2019–2021 and show the distribution of coefficients (akin to your permutation but over timing only).
- Consider a negative-control outcome that should not respond (e.g., providers billing CHIP-only services, if identifiable; or Medicare-only supply from NPPES as a check for address changes).

---

# 4. LITERATURE (missing references + BibTeX)

The paper cites some key items, but for a top journal I expect deeper engagement with (i) health care workforce/access measurement, (ii) Medicaid provider participation and fee elasticity, (iii) “unwinding” early evidence, and (iv) continuous-treatment DiD / dose-response DiD methods.

Below are **specific missing references** that would materially strengthen positioning and methods.

### A. Medicaid fees and provider participation (highly relevant to your “structural factors” story)
1) **Currie & Gruber (1996)** on Medicaid expansions and utilization/participation channels (classic Medicaid paper; helps frame demand vs supply).
```bibtex
@article{CurrieGruber1996,
  author = {Currie, Janet and Gruber, Jonathan},
  title = {Health Insurance Eligibility, Utilization of Medical Care, and Child Health},
  journal = {The Quarterly Journal of Economics},
  year = {1996},
  volume = {111},
  number = {2},
  pages = {431--466}
}
```

2) **Alexander & Schnell (2019 JHE)** on physician behavior/Medicaid (you cite Alexander2019 for scope-of-practice, but not the broader physician response literature; add if relevant; alternatively include papers on physician participation elasticities).
A very commonly cited fee-to-participation paper:
3) **Hackmann, Kolstad & Kowalski (2015 AER)** (provider networks / insurer).
Not purely Medicaid, but relevant on provider network formation; use if you discuss network adequacy.

### B. Access measurement / spatial access and “deserts”
You cite Guagliardo (2004), Ricketts (2007), Graves (2016), Goodman (2023). Add at least one of the modern spatial access measures used in health econ/public health:
1) **Luo & Wang (2003)** on two-step floating catchment area (2SFCA), a foundational spatial accessibility method often used for “deserts.”
```bibtex
@article{LuoWang2003,
  author = {Luo, Wei and Wang, Fahui},
  title = {Measures of Spatial Accessibility to Health Care in a GIS Environment: Synthesis and a Case Study in the Chicago Region},
  journal = {Environment and Planning B: Planning and Design},
  year = {2003},
  volume = {30},
  number = {6},
  pages = {865--884}
}
```

2) **Khan (1992)** (older but classic) on access concepts; optional if you want conceptual grounding.

### C. Difference-in-differences with continuous treatment / dose-response
Your key causal parameter is essentially “effect per unit disenrollment intensity.” That is closer to continuous treatment than binary adoption.
1) **Callaway, Goodman-Bacon & Sant’Anna (2021/2024)** have work on continuous treatments and DiD extensions (depending on which version; if you can’t find a perfect fit, at least acknowledge the literature on generalized DiD).
A widely cited econometrics reference for continuous treatment is:
2) **Hirano & Imbens (2004)** generalized propensity score for continuous treatments (not DiD, but dose-response framing could help).
```bibtex
@article{HiranoImbens2004,
  author = {Hirano, Keisuke and Imbens, Guido W.},
  title = {The Propensity Score with Continuous Treatments},
  journal = {Applied Bayesian Modeling and Causal Inference from Incomplete-Data Perspectives},
  year = {2004},
  pages = {73--84}
}
```
(If you prefer journal-only citations, you could instead cite more recent “generalized DiD” pieces; but the key point is: justify your continuous-dose DiD.)

### D. Wild cluster bootstrap inference
Given 51 clusters and a big panel:
```bibtex
@article{CameronGelbachMiller2008,
  author = {Cameron, A. Colin and Gelbach, Jonah B. and Miller, Douglas L.},
  title = {Bootstrap-Based Improvements for Inference with Clustered Errors},
  journal = {The Review of Economics and Statistics},
  year = {2008},
  volume = {90},
  number = {3},
  pages = {414--427}
}
```
(You already cite it, but if not in bib, include.)

### E. Modern DiD references you cite but must ensure are included in bib
- Sun & Abraham (2021 AER)
- Goodman-Bacon (2021 JEL? actually AER Insights)
- Callaway & Sant’Anna (2021 JoE)
- de Chaisemartin & D’Haultfoeuille (2020 AER)
Provide BibTeX if not already.

---

# 5. WRITING QUALITY (CRITICAL)

### Strengths
- The introduction is clear, policy-motivated, and readable.
- Good narrative structure: motivation → data innovation → descriptive crisis → causal null → policy implications.
- The paper consistently tells the reader what is coming next, which helps.

### Areas to improve (to reach top general-interest polish)
1) **Clarify what a “desert” means when rates are 99%**  
   When you report that 99.6% of county-quarters are psychiatry deserts, a reader’s immediate reaction is: “Then your threshold is not informative or your unit is wrong.” You do note “<1 clinician per 10,000,” but you need to defend why that threshold is meaningful for psychiatry/OB‑GYN and not borrowed from primary care norms. Consider:
   - presenting multiple thresholds (0 per county; 0.1 per 10k; 0.5 per 10k; 1 per 10k),
   - showing distribution plots and “share with zero” separately (you do some of this in sum stats),
   - reframing deserts as **“zero-billing counties”** for certain specialties, which is more interpretable.

2) **Be more explicit about billing vs servicing provider**  
   You state you aggregate on billing NPI “for aggregation,” but many readers will worry you are counting organizations rather than clinicians. You acknowledge this limitation late. This should be moved earlier and addressed empirically.

3) **Magnitudes and interpretation of β**  
   You explain that β is per 100pp disenrollment; but readers will want the effect of a realistic change (e.g., 10pp). Add a line in the Results translating estimates into percent changes:
   - e.g., for Primary Care, β = −0.212 implies a 10pp increase → −0.0212 log points ≈ −2.1% change (approx), with CI.

4) **Over-claiming risk in the abstract**  
   “Remarkably inelastic” is plausible, but you should hedge more: “no detectable effect within 6 quarters” rather than a general conclusion about supply elasticity.

---

# 6. CONSTRUCTIVE SUGGESTIONS (how to make it more impactful)

### A. Validate the “active clinician” measure (highest priority)
This is essential for both the atlas and the null causal result.

1) **Use servicing NPI where possible**
- T‑MSIS includes both billing and servicing NPIs. You should replicate the atlas and the DiD using **servicing NPI counts** (Type 1 clinicians) as the primary outcome, and treat billing NPI results as robustness. If encounter records have missing servicing NPI in some states, report completeness by state/quarter and show robustness to excluding low-completeness states.

2) **Type 1 vs Type 2 NPIs**
- Using NPPES, classify NPIs into individual vs organizational. Recompute outcomes:
  - count of Type 1 active clinicians,
  - count of Type 2 billing organizations,
  - and show which one moves (or doesn’t) with unwinding.
A null in Type 2 could mask real clinician movement.

3) **Address quality / multiple practice locations**
- NPPES practice location can be stale. Consider:
  - restricting to NPIs with recent update dates (NPPES has update timestamps),
  - or using claims-based place-of-service / facility location if available (not sure in your file),
  - or at least a sensitivity excluding NPIs enumerated long ago with no updates.

### B. Fix treatment timing/intensity measurement (very important)
- Replace “post × eventual net decline” with a **time-varying cumulative disenrollment** series:
  \[
  Intensity_{g,t} = \frac{Enroll_{g,peak}-Enroll_{g,t}}{Enroll_{g,peak}}
  \]
  This lets effects line up with actual disenrollment timing and gives a clearer event-study interpretation. It also makes your “total claims as outcome” check more meaningful.

### C. Re-estimate on an “at-risk” sample
Given extreme zeros:
- Restrict to counties with **any pre-period activity** in that specialty (or above some baseline quantile), and separately analyze:
  - extensive margin: Pr(provider count=0),
  - intensive margin among positive counties: log(count) or log(claims).
If the null persists there, it will be much more convincing.

### D. Expand policy relevance of the atlas
1) Compare your desert classifications to:
- HRSA HPSA designations (you discuss conceptually but do not show a crosswalk). A simple county-level cross-tab:
  - HPSA shortage vs T‑MSIS Medicaid desert,
  - false negatives/positives,
  would make the measurement contribution much more compelling.

2) Show a welfare-relevant correlate:
- Even one reduced-form validation would help: deserts predict higher ED use, lower outpatient utilization, or lower preventive care—if you can link to any county-level outcome series (even external aggregated data).

### E. Consider heterogeneity that directly tests mechanisms
- If the key mechanism is that Medicaid is a small share of revenue, effects should be larger where Medicaid share is higher. You have “Medicaid share × time” control; instead, **interact intensity with baseline Medicaid reliance** (state or county) to test that prediction.
- Similarly, interact intensity with **scope-of-practice** (NP full practice authority) to see if provider response differs where substitution is easier.

---

# 7. OVERALL ASSESSMENT

### Key strengths
- Novel and potentially high-value dataset construction (T‑MSIS + NPPES) with a clearly articulated measurement innovation (NP/PA specialty mapping).
- Striking descriptive facts that will interest both researchers and policy audiences.
- Serious effort at modern causal inference: event studies, placebo, permutation inference, Sun-Abraham robustness, clustered SEs, extensive robustness table.

### Critical weaknesses (need to address for publication-quality credibility)
1) **Outcome validity**: billing NPI and NPPES location may not measure county-level clinician supply; suppression/encounter reporting could attenuate effects.
2) **Treatment mismeasurement**: assigning a fixed post “dose” equal to eventual net disenrollment likely blurs timing and biases dynamic effects toward zero.
3) **Zero inflation / thresholding**: desert rates near 99% raise questions about whether the desert definition is meaningful for specialties and whether the regression is identified off a thin, informative subset.

### Specific, high-return fixes
- Rebuild outcomes using **servicing Type 1 NPI counts**, show reporting completeness, and/or restrict to reliable states.
- Use **time-varying disenrollment intensity** by quarter.
- Re-estimate on **positive-baseline (“at-risk”) counties** and use two-part models or PPML.
- Add an empirical validation vs **HPSA**.

Given the promise and fixability, I do not view this as a rejection. But the core claims (especially the causal null) require deeper measurement validation and a cleaner intensity-over-time treatment definition.

DECISION: MAJOR REVISION